Suita, Japan

Akira Kikuchi

This inventor holds 1 USPTO granted patent. Top assignees: Kobe University, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka University. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akira Kikuchi. Retrieved from https://idiyas.com/inventor/akira-kikuchi-g81fff27

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akira Kikuchi: Innovator in Antisense Oligonucleotide Technology

Introduction

Akira Kikuchi is a notable inventor based in Suita, Japan. He has made significant contributions to the field of biomedical innovation, particularly in the development of antisense oligonucleotides. His work focuses on targeting specific molecules to exert therapeutic effects, particularly in cancer treatment.

Latest Patents

Kikuchi holds a patent for an antisense oligonucleotide targeting the ARL4C molecule, along with a nucleic acid drug utilizing this oligonucleotide. The primary aim of this invention is to provide a means to inhibit the expression of the ARL4C molecule in tumor cells. This antisense oligonucleotide, which consists of at least 10 consecutive bases from a specific base sequence, has shown promise in suppressing tumor cell migration and proliferation. Furthermore, when administered systemically, it demonstrates an excellent antitumor effect in vivo.

Career Highlights

Throughout his career, Akira Kikuchi has been associated with prestigious institutions such as Osaka University and the National Institutes of Biomedical Innovation, Health and Nutrition. His work in these organizations has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Kikuchi has collaborated with notable colleagues, including Shinji Matsumoto and Satoshi Obika. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.

Conclusion

Akira Kikuchi's innovative work in antisense oligonucleotide technology represents a significant advancement in cancer treatment. His contributions continue to influence the field of biomedical research and hold promise for future therapeutic developments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…